jama naion semaglutide Study links Wegovy to increased incidence in diabetes patients Semaglutide or Tirzepatide and Optic

Monitoring and follow-up should continue as recommended for tirzepatide therapy, typically including assessment of glycemic control (A1C), weight, gastrointestinal tolerability, and screening for potential adverse effects

Alter the balance of gut bacteria, which affects how food is broken down

The starting dose for weight loss injections is usually 0.25 mg once a week for 4 weeks

A team of international researchers have now found non-diabetic patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are at a higher risk of stomach paralysis, pancreatitis, and bowel obstructions, compared with those taking other weight loss medications

Both are typically used long-term for type 2 diabetes

Wu G, et al